• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Dendritic cell phenotype in severe asthma reflects clinical responsiveness to glucocorticoids
【24h】

Dendritic cell phenotype in severe asthma reflects clinical responsiveness to glucocorticoids

机译：严重哮喘中的树突状细胞表型反映了对糖皮质激素的临床反应性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary Background Subsets of patients with severe asthma remain symptomatic despite prolonged, high‐dose glucocorticoid therapy. We hypothesized that the clinical glucocorticoid sensitivity of these asthmatics is reflected in differences in peripheral blood dendritic cell subsets. Objective To compare peripheral blood leucocyte populations using flow cytometry at baseline and after 2?weeks of systemic glucocorticoid (steroid) treatment to identify immunological differences between steroid‐sensitive ( SS ) and steroid‐resistant ( SR ) asthmatics. Methods Adult severe asthmatics ( SS n?=?12; SR n?=?23) were assessed for their response to 2?weeks of therapy with oral prednisolone. Peripheral blood was obtained before and after therapy and stained for lymphocyte ( CD 3, CD 19, CD 4, CD 8 and Foxp3) and dendritic cell markers (Lineage negative [ CD 3, CD 14, CD 16, CD 19, CD 20, CD 56], HLA ‐ DR +, CD 304, CD 11c, ILT 3 and CD 86). Results A higher median frequency of myeloid DC s ( mDC s) but not plasmacytoid DC s ( pDC s) was observed in the blood of SR as compared to SS asthmatics ( P ?=?.03). Glucocorticoid therapy significantly increased median B cell, but not T cell numbers in both cohorts, with a trend for increased numbers of Foxp3+ Tregs in SS ( P ?=?.07), but not SR subjects. Oral prednisolone therapy significantly reduced the median numbers and frequencies of total DC s and pDC s in both SS and SR asthmatics. Interestingly, the expression of HLA ‐ DR and ILT 3 was also reduced on pDC s in all patients. In contrast, therapy increased the median frequency of mDC s in SS , but reduced it in SR asthmatics. Conclusions Myeloid DC frequency is elevated in SR compared with SS asthmatics, and mDC shows a differential response to oral prednisolone therapy.
机译：发明内容患者严重哮喘患者的子集仍然存在症状，尽管延长了高剂量的糖皮质激素疗法。我们假设这些哮喘学的临床糖皮质激素敏感性反映在外周血树突细胞亚群的差异中。目的将外周血白细胞群体在基线下和2个血糖皮质激素（类固醇）治疗后的流式细胞术进行比较，以鉴定类固醇敏感（SS）和类固醇（SR）哮喘学之间的免疫差异。方法成年严重哮喘学（SS N？= 12; SR N？= 23）被评估对2/2周的口服泼尼松龙治疗的响应。在治疗之前和之后获得外周血并染色淋巴细胞（CD 3，CD 19，CD 4，CD 8和FoxP3）和树突细胞标记物（谱系阴性[CD 3，CD14，CD 16，CD19，CD 20， CD 56]，HLA - DR +，CD 304，CD 11C，ILL 3和CD 86）。结果与SS哮喘学相比，在SS的血液中观察到骨髓DC S（MDC S）的较高中值，但不是在SR的血液中观察到血浆谱系DC S（PDC S）（p？= 03）。糖皮质激素疗法显着增加了中位数B细胞，但两种队列中的T细胞数量增加，SS中的Foxp3 + Tregs数量增加的趋势（P？= 07），但不是SR科目。口服泼尼松龙治疗在SS和SR哮喘中显着降低了总DC S和PDC S的中值和频率。有趣的是，所有患者的PDC S也减少了HLA - DR和ILT 3的表达。相比之下，治疗增加了SS中MDC S的中值，但在SR哮喘中降低了它。结论与SS哮喘学相比，SR的骨髓DC频率升高，MDC显示对口服泼尼松治疗的差异反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号